Approaches for Discussing Clinical Trials with Pediatric Oncology Patients and Their Families.
Lindsay J BlazinAndrea CuvielloHolly L Spraker-PerlmanErica C KayePublished in: Current oncology reports (2022)
The standard paradigm for discussing clinical trial enrollment with pediatric oncology patients and their families inconsistently enables or facilitates true informed consent. Evidence exists to suggest that adopting a shared decision-making approach may improve patient and family understanding. When navigating communication about clinical trials, clinicians should integrate the following evidence-based communication approaches: (1) extend dialogue about clinical trial enrollment across multiple conversations, allowing families space and time to process information independently; (2) use core communication skills such as avoiding jargon, checking for understanding, and responding to emotion. Clinicians should consider factors at the individual, team, organizational, community, and policy levels that may impact clinical trial communication with pediatric cancer patients and their families. This article reviews learnable skills that clinicians can master to optimize communication about clinical trial enrollment with pediatric cancer patients and their families.
Keyphrases
- clinical trial
- palliative care
- phase ii
- end stage renal disease
- open label
- ejection fraction
- chronic kidney disease
- study protocol
- newly diagnosed
- healthcare
- double blind
- phase iii
- mental health
- prognostic factors
- public health
- depressive symptoms
- systematic review
- randomized controlled trial
- autism spectrum disorder
- social media
- young adults